Entrada Therapeutics Projects Q4 EPS Loss $1.32, Revenues Plunge 96.6%
Entrada Therapeutics forecasts a Q4 loss of $1.32 per share, marking a 4,500% year-over-year decline. Revenues are projected at $1.29 million, down 96.6% from the prior year, and consensus EPS estimates have been lowered by 1.5% over the past month.
1. Q4 EPS Forecast
Entrada Therapeutics is expected to report a loss of $1.32 per share for the quarter ended December 2025, representing a 4,500% year-over-year deterioration from the prior year’s results. This sharp downturn underscores escalating expenses or diminishing product revenues in the period.
2. Projected Revenue Drop
Analysts forecast Q4 revenues of just $1.29 million for Entrada, marking a 96.6% decline compared with the year-ago quarter. Such a steep contraction suggests major setbacks in clinical collaborations or product commercialization.
3. Consensus Estimate Revisions
Over the past 30 days, consensus EPS estimates for Entrada have been revised down by 1.5%, reflecting growing market skepticism about near-term financial performance and underlying operational hurdles.